Published in Medical Letter on the CDC and FDA, April 5th, 2009
"NIQs <= 1 may predict poor outcome and identify patients who could benefit from dose escalation. Eligible patients had a viral load >1000 copies/ml on a failing regimen, and began a new protease inhibitor containing regimen at entry. All FDA-approved protease inhibitors available during the study recruitment (June 2002-May 2006)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA